Sign In
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- US Share Prices
- Stock Tips
- Share Chat
- FX
- News & RNS
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Faron Pharmaceuticals Share News (FARN)
FARN Share
Price
FARN Share
News
FARN Share
Chat
FARN Share
Trades15
FARN
Live RNS
FARN Share
Charts
FARN Level 2
Console
FARN Live
Share Price
FARN Broker
Ratings
FARN Directors
Deals
FARN Financial
Diary
FARN
Fundamentals
FARN Short
Positions
FARN
Media
FARN Company
Research
FARN Company
Timeline
Share Price Information for Faron Pharmaceuticals (FARN)
Last checked at -
Last checked at 
Intraday Faron Pharmaceuticals Share Chart
Faron Pharmaceuticals Notes Study Supporting Clevegen Programme
LONDON (Alliance News) - Faron Pharmaceuticals Oy on Monday said an article published in the Journal of Immunology has outlined the functional role of the company's Clever-1 treatment, part of its Clevegen cancer immunotherapy antibody programme.
Faron, which floated in London earlier this month, said the data published in the study supported Clever-1 as an immuosuppresive molecule and supports the use of Clevegen as an immunotherapy product.
"We are working hard to advance our Clevegen programme, as announced recently, towards clinical use as a new onco-immunological alternative," said Faron Chief Executive Markku Jalkanen.
Shares in Faron were trading flat at 275.00 pence on Monday.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Latest FARN News
- UK earnings, trading statements calendar - next 7 days
25 Feb 2026 - Director dealings: Victoria non-exec invests, Faron Pharma CFO sells entire holding
13 Jan 2026 - Faron issuing second tranche of unsecured convertible bonds
11 Dec 2025 - Faron appoints former AstraZeneca Netherlands finance chief as CFO
1 Dec 2025 - Faron Pharmaceuticals appoints new finance chief
1 Dec 2025 - Faron says new data reinforces promise of bone marrow cancer drug
20 Oct 2025 - Faron strengthens bexmarilimab potential with fresh trial data
20 Oct 2025 - Faron Pharmaceuticals narrows loss as cancer treatment trials continue
27 Aug 2025
Related News
IN BRIEF: Faron Pharmaceuticals fined EUR30,000 by Nasdaq Helsinki
Faron Pharmaceuticals Ltd - Turku, Finland-based cancer drug developer - Says the Disciplinary Committee of Nasdaq Helsinki Ltd has imposed an EUR30,0...
WINNERS & LOSERS: James Cropper sees earnings up; Block sells stake
(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Tuesday.
Faron Pharmaceuticals News
Director dealings: Victoria non-exec invests, Faron Pharma CFO sells entire holding
(Sharecast News) - Shares in Victoria saw director support on Tuesday, after the group disclosed that non-executive director Steve Callaghan purchased...
Faron issuing second tranche of unsecured convertible bonds
(Sharecast News) - Faron Pharmaceuticals said on Thursday that its board had approved the issue of the second tranche of its amortising senior unsecur...
Faron appoints former AstraZeneca Netherlands finance chief as CFO
(Alliance News) - Faron Pharmaceuticals Ltd on Monday said it has appointed Jurriaan Dekkers as the company’s chief financial officer.
Faron Pharmaceuticals appoints new finance chief
(Sharecast News) - Faron Pharmaceuticals announced the appointment of Jurriaan Dekkers as its chief financial officer on Monday, strengthening its sen...
Faron says new data reinforces promise of bone marrow cancer drug
(Alliance News) - Faron Pharmaceuticals Ltd on Monday said updated biomarker data strengthened the clinical profile of bexmarilimab, its lead treatmen...
Faron strengthens bexmarilimab potential with fresh trial data
(Sharecast News) - Faron Pharmaceuticals said on Monday that updated results from its phase one and two 'BEXMAB' study showed further improvement in t...
Faron Pharmaceuticals narrows loss as cancer treatment trials continue
(Alliance News) - Faron Pharmaceuticals Ltd on Wednesday posted an improvement in half-year results with "strong and steady progress" for its immunoth...
Follow the stocks
